Skip to main content

Table 1 General characteristics of study population at enrolment according to study arms

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Parameters

Pyronaridine-artesunate

(PA), N = 224

Artemether–lumefantrine

(AL), N = 296

Sex (male), n (%)

95 (42.41)

133 (44.93)

Age, mean ± SD (in year)

8.96 ± 6.52

9.29 ± 7.56

Age groups (in year), n (%)

  

 ≤ 5

58 (25.9)

84 (28.38)

 > 5 to ≤ 15

138 (61.61)

171 (57.77)

 > 15

28 (12.5)

41 (13.85)

Weight, mean ± SD

25.99 ± 14.46

26.33 ± 14.70

Height, mean ± SD

124.47 ± 24.86

124.76 ± 25.89

Major symptoms, n (%)

  

 Fever

224 (100)

296 (100)

 Headache

180 (80.36)

216 (72.97)

 Anorexia

123 (54.91)

135 (45.61)

 Vomiting

112 (50.00)

126 (42.57)

 Abdominal pain

133 (59.38)

159 (53.72)

Plasmodium species, n (%)

  

 P. falciparum

222 (99.11)

291 (98.31)

 P. malariae

1 (0.45)

4 (1.35)

 P. ovale

1 (0.45)

1 (0.34)

 P. falciparum density, mean ± SD §

16,218 ± 9.50

14,739 ± 9.18

ALT (IU /L), mean ± SD

23.63 ± 11.16

23.61 ± 15.09

AST (IU /L), mean ± SD

29.16 ± 14.83

29.37 ± 15.56

ALP (IU/L), mean ± SD

225.52 ± 95.93

223.98 ± 92.82

Total bilirubin (mg/dL), mean ± SD

1.38 ± 1.06

1.24 ± 0.91

Direct bilirubin (mg/dL), mean ± SD

0.43 ± 0.29

0.41 ± 0.27

Haemoglobin (g/dL), mean ± SD

10.69 ± 1.48

10.49 ± 1.51

  1. SD: Standard deviation; CI: Confidence interval; P: Plasmodium; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; p: p-value; IU/L: International Units per litre; mg/dl: milligrams per decilitre; g/dl: grams per decilitre; §: geometric mean